Pharmacotherapy for chronic obstructive pulmonary disease
10.5124/jkma.2018.61.9.545
- Author:
In Ae KIM
1
;
Yong Bum PARK
;
Kwang Ha YOO
Author Information
1. Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea. bfspark2@gmail.com
- Publication Type:Original Article
- Keywords:
Pulmonary disease, chronic obstructive;
Beta2-agonist;
Cholinergic antagonists;
Inhaled corticosteroid;
Phosphodiesterase 4 inhibitors
- MeSH:
Bronchodilator Agents;
Cholinergic Antagonists;
Cyclic Nucleotide Phosphodiesterases, Type 4;
Disease Progression;
Drug Therapy;
Exercise Tolerance;
Humans;
Mortality;
Phosphodiesterase 4 Inhibitors;
Pulmonary Disease, Chronic Obstructive;
Risk Factors
- From:Journal of the Korean Medical Association
2018;61(9):545-551
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The goals of management of stable chronic obstructive pulmonary disease (COPD) are to reduce both current symptoms and future risks with minimal side effects from treatment. Identification and reduction of exposure to risk factors are important in the treatment and prevention of COPD. Appropriate pharmacologic therapy can reduce symptoms and exacerbations, and improve health status and exercise tolerance. To date, none of the existing medications for COPD has been shown to modify disease progression or reduce mortality. The classes of medication are bronchodilators including beta2-agonist, anticholinergics and anti-inflammatory drug including inhaled corticosteroid and phosphodiesterase-4 inhibitor such as roflumilast. Each treatment regimen needs to be individualized as the relationship between severity of symptoms, airflow limitation and severity of exacerbation can differ between patients.
